St. Jude Scientists Discover How to Restore Dendritic Cell Function to Enhance Cancer Immunotherapy
核心洞察
St. Jude researchers discovered that tumors disable dendritic cells by reducing their mitochondrial fitness, preventing effective anticancer immune responses.
The study identified OPA1 (搜索) and NRF1 (搜索) proteins as key regulators of mitochondrial-nuclear communication that become downregulated in tumor environments.
Combining dendritic cells with enhanced mitochondrial activity and immune checkpoint blockade synergistically improved tumor control and survival in preclinical models.
St. Jude Children's Research Hospital scientists have uncovered a critical mechanism by which tumors evade immune surveillance and developed a strategy to restore immune function that could enhance cancer immunotherapy effectiveness. The research, published in Science, reveals how tumors disable dendritic cells—the immune system's "gatekeeper" cells—by compromising their energy production, and demonstrates that restoring mitochondrial function can significantly improve treatment outcomes.
Tumor-Induced Mitochondrial Dysfunction
Dendritic cells serve as crucial activators of cytotoxic immune cells that destroy cancer. However, the research team discovered that within the nutrient-sparse tumor microenvironment, dendritic cells progressively lose their energy-producing mitochondrial activity. This metabolic disruption drives dendritic cell dysfunction and weakens the body's immune defenses against cancer.
"We found that tumors reprogram mitochondrial metabolism in dendritic cells, reducing their ability to activate the immune system against cancer," said Hongbo Chi, PhD, St. Jude Department of Immunology chair. "By enhancing mitochondrial function, we could restore dendritic cell activity and rescue antitumor immunity."
The researchers identified a specific signaling axis composed of two proteins, OPA1 (搜索) and NRF1 (搜索), that regulate communication between mitochondria and the nucleus. Their expression was greatly downregulated in dendritic cells during tumor progression, acting as a metabolic switch that signals an energy crisis and causes dendritic cells to shut down their immunogenic activity.
Synergistic Therapeutic Effects
To test the therapeutic potential of their findings, the investigators compared treatment outcomes in tumor-bearing mice using dendritic cells with enhanced mitochondrial activity alone, immune checkpoint blockade alone, or both treatments combined. The combination therapy produced the most pronounced therapeutic effects.
"We saw the most pronounced therapeutic effect in mice treated with the combination of dendritic cells that had high mitochondrial activity and immune checkpoint blockade," said co-first author Zhiyuan You, PhD, St. Jude Department of Immunology. "Those combinations synergistically slowed or stopped tumor growth and extended survival far more than either treatment alone."
The therapeutic benefits extended beyond immediate tumor control. When researchers exposed treated mice to new tumors months later, those animals successfully stopped the new tumor growth, indicating that durable, long-term immune memory had been established.
Mechanistic Insights and Future Implications
The study provides detailed mechanistic insights into how the tumor microenvironment directly regulates dendritic cell function. Co-first author Jiyeon Kim, PhD, St. Jude Department of Immunology, explained: "We're seeing a direct regulation of dendritic cells by the tumor microenvironment. We have characterized how that results in mitochondrial reprogramming of dendritic cells to benefit cancer, giving us new opportunities to reverse the process."
The research demonstrates that introducing dendritic cells with high mitochondrial activity into tumors in preclinical mouse models can restore immunogenic activity and improve tumor control. This approach addresses a fundamental limitation of current immunotherapies, which have shown great success in many malignancies but have not been effective across all cancer types.
"These findings reinforce the central role of dendritic cells in cancer immunity," Chi said. "By exploring their mitochondrial function in the tumor microenvironment, we have provided a proof-of-principle of how we may be able to improve the next generation of immunotherapies."
The study's mechanistic insights provide a foundation for developing new strategies to rewire dendritic cell function and enhance cancer treatments, potentially offering hope for patients whose cancers have not responded to existing immunotherapies.